New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI

2022 Recap: New Treatments and Approaches in #prostatecancer | #markscholzmd | PCRISee more

Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRISee more

PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022See more

PSMA & Lutetium-177 in 2022 | Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 4See more

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRISee more